EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer von Hastings, K., Yu, H.A., Wei, W., Sanchez-Vega, F., DeVeaux, M., Choi, J., Rizvi, H., Lisberg, A., Truini, A., Lydon, C.A., Liu, Z., Henick, B.S., Wurtz, A., Cai, G., Plodkowski, A.J., Long, N.M., Halpenny, D.F., Killam, J., Oliva, I., Schultz, N., Riely, G.J., Arcila, M.E., Ladanyi, M., Zelterman, D., Herbst, R.S., Goldberg, S.B., Awad, M.M., Garon, E.B., Gettinger, S., Hellmann, M.D., Politi, K.

Volltext

Fundamental studies of the adhesion of explosives to textile and non-textile surfaces von Yu, H.A, Becker, T, Daeid, N. Nic, Lewis, S.W

Volltext

EGFR Exon 20 Alterations in Lung Adenocarcinomas and Their Impact on Overall Survival and Response to EGFR TKI von Naidoo, J, Sima, C.S, Rodriguez, K, Busby, N, Arcila, M.E, Yu, H.A

Volltext

Post-dural puncture headache after spinal anesthesia and perioperative blood pressure von Chung, J.M, Kim, J.K, Kim, J.Y, Park, K.I, Yu, H.A

Volltext

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? von Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Volltext

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? von Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Volltext

Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy? von Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Volltext

Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation? von Patel, S, Rimner, A, Foster, A, Zhang, Z, Woo, K.M, Yu, H.A, Riely, G.J, Wu, A.J

Volltext

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non smal... von Soria, J, Sequist, L.V, Goldman, J.W, Wakelee, H.A, Gadgeel, S.M, Varga, A, Yu, H.A, Solomon, B.J, Ou, S.H, Papadimitrakopoulou, V, Oxnard, G.R, Horn, L, Dziadziuszko, R, Chao, B, Spira, A.I, Liu, S, Mekhail, T, Matheny, S, Litten, J, Camidge, R.D

Volltext

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib von Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D.

Volltext

POSing the question: MARIPOSA-2, do the ends justify the means? von Chen, M F, Piotrowska, Z, Yu, H A

Volltext

COVID-19 in patients with lung cancer von Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G., Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng, J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik, P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza, M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D.

Volltext

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing von Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J.

Volltext

1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) von Yu, H.A., Cantero, F., Kim, B., Lee, M., Wu, E., Sternberg, D.W., Jänne, P.A.

Volltext

EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US von Sabari, J.K., Yu, H.A., Mahadevia, P., Liu, Y., Demirdjian, L., Sultan, A.A., Chen, Y.H., Wang, X., Passaro, A.

Volltext

P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers von Sui, J.S., Chen, M.F., Wilcox, J., Yang, S.R., Li, B.T., Riely, G.J., Offin, M., Yu, H.A., Kris, M.G., Drilon, A.E.

Volltext

1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression... von Mok, T.S.K., Wu, Y-L., Nishio, M., Reck, M., Wu, E., Sternberg, D.W., Esker, S., Yu, H.A.

Volltext

APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas von Selenica, P., Marra, A., Choudhury, N.J., Gazzo, A., Falcon, C.J., Patel, J., Pei, X., Zhu, Y., Ng, C.K.Y., Curry, M., Heller, G., Zhang, Y.-K., Berger, M.F., Ladanyi, M., Rudin, C.M., Chandarlapaty, S., Lovly, C.M., Reis-Filho, J.S., Yu, H.A.

Volltext

1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab von Passaro, A., Yu, H.A., Nguyen, D., Lee, V.H.F., Soo, R.A., Kim, S.H., Daga, H., Tan, D.S.W., Kim, S-W., Juan Vidal, O.J., Piotrowska, Z., Keeton, E.K., Liu, T., Li, S., Jones, J., Ruiter, G.

Volltext

EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma von Quintanal-Villalonga, A., Taniguchi, H., Zhan, Y.A., Rekhtman, N., Houck-Loomis, B., Koche, R.P., Yu, H.A., Sen, T., Rudin, C.M.

Volltext